News

Indian Pharma Majors Breathe Easy as US Spares Sector from Reciprocal Tariffs

Picture of By Pharmautility
By Pharmautility

May 6, 2025

Table of Contents

Large Indian drug makers, some of which get as much as half their revenue from the US market, were relieved as President Donald Trump spared the sector from reciprocal tariffs.

The market was expecting a 10% tariff on pharma imports from India. Even if half of that was passed on to patients or absorbed by insurers, still large Indian pharma companies would have faced a 3-5% impact on their earnings in fiscal 2027, according to sector analysts and industry experts.

Related Posts